Precision BioSciences reports biopsy evidence of cccDNA elimination in ELIMINATE-B trial of PBGENE-HBV for chronic hepatitis B

Precision BioSciences

Precision BioSciences

DTIL

0.00
  • Precision BioSciences disclosed new, late-breaking ELIMINATE-B trial data on PBGENE-HBV at the EASL Congress 2026; results were presented there.
  • Liver biopsy findings supported the therapy’s intended ability to disable the viral reservoir driving chronic hepatitis B, a result the company framed as a field first.
  • Blood biomarker readouts aligned with the biopsy signal, reinforcing evidence of sustained antiviral activity across treated patients.
  • Safety profile remained manageable with no dose-limiting toxicities; infusion-related reactions were most common, with mitigation steps introduced for hypotension and liver-enzyme spikes.
  • Next steps include enrolling more patients, collecting additional biopsy data, preparing for nucleoside-analog withdrawal, and selecting a dosing schedule for a later-stage expansion; updates targeted by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260526374454) on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.